Cerbios-Pharma joins PROVEO for the 8th ADC World Berlin 2018
Press Release | Cerbios-Pharma SA
MARCH 27, 2018
Lugano, Switzerland: – Cerbios-Pharma SA, part of the PROVEO alliance and focused on HPAI, Cytotoxic molecules and ADCs manufacturing, (Cerbios) will participate at the upcoming ADC World conference in Berlin.
Cerbios, along with its PROVEO partners, is returning to the European ADC World congress following a fruitful participation at the September 2017 ADC World USA event in San Diego.
cGMP ADC development services
Cerbios delegates (PROVEO Booth 3 at Berlin’s ProArte Maritim Hotel) will present a range of integrated ADC development and cGMP services offered in conjunction with its Alliance partners, AGC Biologics and Oncotec.
“We look forward to this opportunity to discuss details of our innovative service offerings and to network with complementary service providers and potential customers, including startup and midsize pharma companies,” commented Cerbios-Pharma CEO, Dr. Gabriel Haering.
“We’ll be able to show them how we can deliver integrated ADC services with overall project time compression,” Dr. Haering added.
Payload and conjugation scale-up
Cerbios can offer cGMP manufacturing capabilities for toxic payloads and ADCs, as well as an innovative focus on conjugation process development and scale up.
During recent years, the company has deepened its core capabilities in HPAIs, Probiotics and Recombinant Proteins, while extending its CMO offers to ADCs bioconjugation.
Cerbios-Pharma SA is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners worldwide. Cerbios specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of fine chemicals and biologicals.
Cerbios Chemical Division offers exclusive, third party manufacturing services for HPAIs while Biological Division produces monoclonal antibodies, recombinant proteins and pharma probiotics.
Cerbios provides full CMC support to its worldwide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with CMC Biologics of Denmark, together with Germany’s Oncotec.
PROVEO can offer a one-stop shop service from substance development through to full finish.
About ADC World Europe 2018
The ADC World conference is the industry’s longest standing and most comprehensive event devoted to Antibody Drug Conjugate (ADC) technology and solutions.
The event aims to generate new insights and connections to promote development of more clinically impactful ADCs.
The 8th European conference, ADC World 2018, will be a three-day event opening March 26 at the ProArte Maritim Hotel, Berlin.
The Berlin conference will number some 320 industry representatives from more than 140 organizations.
The meeting will feature a comprehensive three-track program covering every element of ADCs from discovery, development, manufacturing and clinical applications.
The event is organized by Hanson Wade with more information at: http://worldadc-europe.com.
Chiara Brusadelli, Commercial Operations Assistant Manager, Cerbios-Pharma SA
Tel: +41 91 985 6311